BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets open in 4 hrs 4 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
289.54+4.24 (+1.49%)
At close: 4:00 PM EST

300.50 10.96 (3.79%)
Pre-Market: 5:16 AM EST

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close285.30
Bid298.00 x 100
Ask302.68 x 100
Day's Range278.58 - 292.97
52 Week Range223.02 - 333.65
Avg. Volume1,607,062
Market Cap63B
PE Ratio (TTM)16.37
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals8 hours ago

    Biogen stock gains on leaked Alzheimer's drug data

    Shares of Cambridge-based Biogen rose slightly on Thursday after positive data from an upcoming presentation on its experimental Alzheimer’s drug was leaked online. Biogen (BIIB) is scheduled to present early-stage data on aducanumab at a medical industry conference in San Diego on Friday, but an embargoed abstract of the presentation was apparently leaked Thursday afternoon. Shares of Biogen were up about 1.5 percent at the close of trading.

  • Biogen, Eli Lilly Release Trial Data On Their Alzheimer's Drugs
    Investor's Business Daily8 hours ago

    Biogen, Eli Lilly Release Trial Data On Their Alzheimer's Drugs

    Biogen and Eli Lilly released data on their experimental Alzheimer's treatments on Thursday.

  • Reuters9 hours ago

    Further promising data seen with Biogen Alzheimer's drug -study

    Gradually increasing the dose of Biogen Inc's experimental Alzheimer's disease drug appeared to reduce the risk of brain swelling compared to higher fixed doses, interim 12-month results from a small study released on Thursday showed. The closely watched drug, aducanumab, led to significant reductions in amyloid plaques in the brain compared with a placebo among the 31 early-stage Alzheimer's patients given titrated, or gradually increased dosing, according to data from the Phase I study. "These data appear solid to us, and if anything provide additional confidence in the program and viability of the titration regimen," Evercore ISI analyst John Scotti said in a research note late on Thursday.